🇺🇸 FDA
Patent

US 10106620

Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells

granted A61KA61K39/39558A61P

Quick answer

US patent 10106620 (Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K39/39558, A61P, A61P35/02, A61P37/00